Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.
暂无分享,去创建一个
Jeffrey E Gershenwald | Merrick I Ross | Natale Cascinelli | Charles M Balch | Martin C Mihm | V. Sondak | M. Mihm | M. Ross | J. Kirkwood | A. Cochran | A. Eggermont | J. Gershenwald | C. Balch | S. Soong | N. Cascinelli | D. Coit | K. McMasters | D. Morton | D. Byrd | S. Leong | T. Johnson | Kelly M McMasters | Stanley P Leong | Shouluan Ding | Alistair J Cochran | Seng-Jaw Soong | John M Kirkwood | John F Thompson | Vernon K Sondak | David R Byrd | Daniel G Coit | Shouluan Ding | Alexander M Eggermont | Donald L Morton | Timothy Johnson | J. Thompson
[1] D. Cox. Regression Models and Life-Tables , 1972 .
[2] N Cascinelli,et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Gönen,et al. Positive Nonsentinel Node Status Predicts Mortality in Patients with Cutaneous Melanoma , 2008, Annals of Surgical Oncology.
[4] S. Soong,et al. Clinical Significance of Occult Metastatic Melanoma in Sentinel Lymph Nodes and Other High-risk Factors Based on Long-term Follow-up , 2005, World Journal of Surgery.
[5] K. Henry,et al. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. , 2002, European journal of cancer.
[6] R. Scolyer,et al. The Prognostic Importance of Tumor Mitotic Rate Confirmed in 1317 Patients With Primary Cutaneous Melanoma and Long Follow-Up , 2004, Annals of Surgical Oncology.
[7] D. Coit,et al. A prospective randomized trial of perioperative cefazolin treatment in axillary and groin dissection. , 1991, Archives of surgery.
[8] C. Balch,et al. Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Elashoff,et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. , 1982 .
[10] H. Drepper,et al. The prognosis of patients with stage III melanoma prospective long‐term study of 286 patients of the fachklinik hornheide , 1993, Cancer.
[11] D. Tyler,et al. Long-Term Survival in 2,505 Patients With Melanoma With Regional Lymph Node Metastasis , 2002, Annals of surgery.
[12] A. Chang,et al. Prognostic Significance of a Positive Nonsentinel Lymph Node in Cutaneous Melanoma , 2009, Annals of Surgical Oncology.
[13] Jeffrey E. Lee,et al. Revised American Joint Committee on Cancer Staging Criteria Accurately Predict Sentinel Lymph Node Positivity in Clinically Node-Negative Melanoma Patients , 2003, Annals of Surgical Oncology.
[14] Xianglin L. Du,et al. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Mocellin,et al. Clinical Considerations on Sentinel Node Biopsy in Melanoma from an Italian Multicentric Study on 1,313 Patients (SOLISM–IMI) , 2009, Annals of Surgical Oncology.
[16] S. Singletary,et al. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. , 1989, Archives of surgery.
[17] D. Coit,et al. Axillary dissection in melanoma. Prognostic variables in node-positive patients. , 1990, Annals of surgery.
[18] N. Cascinelli,et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Ross,et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Ross,et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Rutkowski,et al. The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2–pT3) , 2008, Annals of Surgical Oncology.
[22] Yuting Zhang,et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma , 2003, Cancer.
[23] M. Ross,et al. Improved Staging of Node-Negative Patients With Intermediate to Thick Melanomas (>1 mm) With the Use of Lymphatic Mapping and Sentinel Lymph Node Biopsy , 2001, Annals of Surgical Oncology.
[24] A. Stromberg,et al. Correlation Between Prognostic Factors and Increasing Age in Melanoma , 2004, Annals of Surgical Oncology.
[25] B K Armstrong,et al. Melanoma of the skin. , 1984, British medical bulletin.
[26] V. Sondak,et al. Sentinel node biopsy and standard of care for melanoma. , 2009, Journal of the American Academy of Dermatology.
[27] R. Elashoff,et al. Improved Long-term Survival After Lymphadenectomy of Melanoma Metastatic to Regional Nodes , 1991 .
[28] Martin F. Mihm,et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] C. Balch,et al. A Multifactorial Analysis of Melanoma: III. Prognostic Factors in Melanoma Patients with Lymph Node Metastases (Stage II) , 1981, Annals of surgery.
[30] R. Scolyer,et al. The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma , 2006, Journal of cutaneous pathology.
[31] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D L Morton,et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. , 1999, Annals of surgery.
[33] M. Berwick,et al. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma , 2005, Journal of cutaneous pathology.
[34] D. Elder,et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Jeffrey E. Lee,et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. Elashoff,et al. Sentinel-node biopsy or nodal observation in melanoma. , 2006, The New England journal of medicine.
[37] D L Morton,et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.
[38] C. Balch,et al. Sentinel-node biopsy in melanoma. , 2006, The New England journal of medicine.